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MHC molecules associated with autoimmunity possess known structural features that limit 
the repertoire of peptides that they can present. Such limitation gives a selective advantage 
to TCRs that rely on interaction with the MHC itself, rather than with the peptide residues. 
At the same time, negative selection is impaired because of the lack of negatively selecting 
peptide ligands. The combination of these factors may predispose to autoimmunity. We 
found that mice with an MHC class II–peptide repertoire reduced to a single complex 
demonstrated various autoimmune reactions. Transgenic mice bearing a TCR (MM14.4) 
cloned from such a mouse developed severe autoimmune dermatitis. Although MM14.4 
originated from a CD4
 
 
 
 T cell, dermatitis was mediated by CD8
 
 
 
 T cells. It was established 
that MM14.4
 
 
 
 is a highly promiscuous TCR with dual MHC class I/MHC class II restriction. 
Furthermore, mice with a limited MHC–peptide repertoire selected elevated numbers of 
TCRs with dual MHC class I/MHC class II restriction, a likely source of autoreactivity. Our 
findings may help to explain the link between MHC class I responses that are involved in 
major autoimmune diseases and the well-established genetic linkage of these diseases with 
MHC class II.
 
Genetic predisposition to autoimmune disorders,
such as type 1 diabetes and rheumatoid arthritis,
is associated with the MHC (1, 2), although the
nature of this association is not entirely clear. In
addition, most of the established linkages are to
MHC class II, whereas MHC class I–reactive
CD8
 
 
 
 T cells play a critical role in the devel-
opment of organ-specific diseases, such as type
1 diabetes. Structural studies of MHC class II
molecules associated with autoimmunity re-
vealed that these molecules have specific features
that introduce a bias in the repertoire of pep-
tides that can be bound (3–5). For example,
human and mouse MHC class II molecules asso-
ciated with type 1 diabetes have an identical
amino acid substitution (Asp
 
 
 
57
 
 
 
Ser) in the
 
 
 
 chain that leads to a change in the overall
properties of class II molecules (6). Resolution
of the structure of I-A
 
g7
 
 molecules (4, 5) re-
vealed that this MHC class II protein preferen-
tially, although not exclusively, binds peptides
with acidic P9 residues. Similarly, HLA-DR4
(DRA
 
*
 
0101, DRB1
 
*
 
0401), associated with a
high frequency of rheumatoid arthritis, possesses
a Lys at position 
 
 
 
71, which also leads to a bias
in peptide repertoire; peptides with negatively
charged amino acids in position p4 bind DR4
preferentially (3, 7).
We reasoned that limitation of peptide diver-
sity should influence negative selection of T
cells—which is peptide-specific—and their posi-
tive selection. During positive selection, a limited
peptide repertoire should provide an advantage
to TCRs that are less dependent on interac-
tions with specific peptides, but which rely on
recognition of MHC molecules per se, with
possible assistance from the coreceptor pro-
teins. This unusual TCR repertoire containing
TCRs with autoreactive potential, in turn,
may be supported by the impairment of nega-
tive selection.
To test this hypothesis, we took advantage
of a transgenic mouse strain in which MHC
class II/peptide complex diversity is dimin-
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ished to a single variety: the I-A
 
b
 
 complex with a peptide de-
rived from the E
 
 
 
 protein (A
 
b
 
Ep; reference 8). Mice ex-
pressing A
 
b
 
Ep were shown to select a significant proportion
of “autoreactive” T cells activated by WT A
 
b
 
 molecules (8).
Here, we describe various indicators of autoimmunity in
A
 
b
 
Ep mice. Moreover, when TCR genes cloned from an
A
 
b
 
-reactive CD4
 
 
 
 T cell (MM14.4) isolated from an A
 
b
 
Ep
mouse were expressed as transgenes, the TCR-transgenic
mice developed autoimmunity—an inflammatory skin dis-
ease. Surprisingly, dermatitis was caused by MM14.4
 
 
 
CD8
 
 
 
T cells, which suggested that these T cells carried a TCR
with dual MHC class I/MHC class II restriction. Further ex-
amination confirmed that conclusion and revealed that A
 
b
 
Ep
mice select elevated numbers of dual–MHC-restricted
TCRs (dr-TCRs) that may contribute to a potential pool of
autoreactive T lymphocytes.
 
RESULTS
Mice with biased MHC–peptide repertoire develop 
autoimmune reactions
 
To determine whether animals with limited MHC-peptide
repertoire are prone to autoimmunity, we histologically ex-
amined multiple organs from A
 
b
 
Ep mice (Fig. 1). Although
no obvious changes were found in young (
 
 
 
3 mo) mice
(unpublished data), mononuclear infiltrates in multiple or-
gans were detected in older animals (
 
 
 
6 mo). 
 
 
 
30% of mice
have shown lymphocytic infiltrates in the pancreatic islets
and around blood vessels (perivasculitis; Fig. 1 A). In addi-
tion, sialoadenitis, thyroiditis, and interstitial nephritis were
observed. This latter group of lesions is not unusual in aging
mice of common mouse strains. A
 
b
 
Ep mice have been de-
rived by a complicated breeding scheme that included sev-
eral genetic backgrounds (8). They underwent continuous
inbreeding in our facility, and are considered inbred. They
are congenic to mice lacking MHC class II A
 
b
 
 molecules and
the invariant chain (Ii), termed C2
 
 
 
 mice (8). Thus, A
 
b
 
Ep
mice could have lesions seen in other common strains.
However, infiltration of the pancreatic islets is not common
at all, except in NOD mice that are prone to spontaneous
type 1 diabetes. We found that the infiltrates contained
CD4- and CD8-positive T cells (Fig. 1 B) which indicates
that limited peptide repertoire presented to the TCRs by
MHC class II molecules also may lead, in some manner, to
activation of autoimmune CD8
 
 
 
 T cells.
We also searched for signs of generalized autoimmunity,
such as generation of antinuclear antibodies (ANAs), but
did not detect them. However, that can be explained by
lack of expression of the Ii in A
 
b
 
Ep mice, which makes their
B cells not fully functional (9, 10). We then examined the
sera of A
 
b
 
Ep mice expressing Ii for the presence of ANAs
Figure 1. Mice with extremely limited and partially limited MHC 
peptide repertoires are prone to autoimmunity. (A) Histologic exami-
nation of organs from AbEp mice  6-mo-old revealed mononuclear infil-
trates in different organs. (B) Lymphoid infiltrates around a large perito-
neal blood vessel (top left), and a pancreatic islet (right and bottom left). 
Hematoxylin-eosin staining (top), anti–CD4-FITC (bottom left), and 
anti–CD8-FITC (bottom right). LN, lymph node. (C) ANAs in the sera of 
 5-mo-old AbEp mice expressing Ii. Negative control B6 serum scored “0,” 
serum from B6lpr/lpr mouse scored “10,” while a serum from a representative 
AbEp,Ii  mouse scored “5” on a relative scale. (D) Distribution of ANA 
presence and titers in AbEp,Ii  mice and control mice. All data are for sera 
dilution of 1:50. 
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(Fig. 1 C). We found that ANAs clearly were present in
many (
 
 
 
60%) mature A
 
b
 
Ep,Ii
 
 
 
 mice. MHC–peptide reper-
toire in A
 
b
 
Ep,Ii
 
 
 
 mice is significantly more diverse than in
A
 
b
 
Ep mice as a result of replacement of the covalently
bound E
 
 
 
 peptide by a diverse set of peptides (11).
A
 
b
 
Ep,Ii
 
 
 
 mice still have 
 
 
 
30% MHC class II molecules oc-
cupied by E
 
 
 
 peptide. This assumption is based on staining
with A
 
b
 
Ep-specific antibodies Y-Ae and with the 25–9-17
antibody that fails to recognize this complex (12). These
data are in concordance with previous findings of B cell–
mediated autoimmunity in A
 
b
 
Ep,Ii
 
 
 
 mice (13). Thus, even
partial limitation of MHC–peptide repertoire predisposes to
autoimmunity.
 
MM14.4 TCR transgenic animals develop 
autoimmune dermatitis
 
Because the manifestations of autoimmunity in A
 
b
 
Ep mice
were relatively mild (which can be explained by the pres-
ence of suppressor T cells in these mice (Fig. S1, available
at http://www.jem.org/cgi/content/full/jem.20050198/
DC1), we sought to find whether “autoimmunity-prone”
TCRs generated in A
 
b
 
Ep mice would cause an illness when
expressed as monoclonal transgenes. For that, ConA-acti-
vated blasts from A
 
b
 
Ep lymph nodes were fused to
BW5147 thymoma cell line, and the resulting hybridomas
were selected for the reactivity with the WT MHC class II
A
 
b
 
 molecules. A TCR from one such CD4
 
 
 
 hybridoma
(MM14.4) was cloned and microinjected into oocytes.
Four independent MM14.4 TCR transgenic strains (500,
581, 675, and 690) expressed cointegrated MM14.4 TCR
 
 
 
(V
 
 
 
2.5-J
 
 
 
20 
 
 
 
 TRAV14D-2-TRAJ26) and TCR
 
 
 
(V
 
 
 
16.2-D
 
 
 
2.1-J
 
 
 
2.1 
 
 
 
 TRBV3-TRBJ2-1). All of them
developed lesions in the skin, which suggested that random
transgene integration was not responsible for the disease.
Infection did not cause the lesions because mice had no cu-
taneous pathogens, and nontransgenic littermates were al-
ways disease-free. Skin lesions (Fig. 2, d–k) were character-
ized by scaling and thickening of the epidermis, and
mononuclear infiltrate (consisting primarily of lympho-
cytes) in the epidermis and dermis. Parakeratosis (thickened
stratum corneum with retention of nuclei) was observed
(Fig. 2, e, f, and h) as well as occasional pustules within the
stratum corneum consisting of degenerating neutrophils
and proteinaceous debris (Fig. 2 g). The epidermal hyper-
plasia was characterized by the loss of expression of keratins
1 and 10, and by gain of expression of keratin 6 (typical for
hyperplasia; Fig. 2, i–k). These characteristics resemble
human psoriasis. The hair growth also was affected in
MM14.4 mice, which was different from human disease,
although psoriatic lesions in the scalp accompanied by hair
loss have been described in humans (14, 15). Skin infiltrates
were found microscopically as early as 10–12 d post par-
tum, and the onset of visible dermatitis was observed at
about the time of weaning (3 wk). Dermatitis severity then
peaked sharply, but subsided gradually in most mice.
 
CD8
 
 
 
 T cells are responsible for the development of the 
autoimmune dermatitis in MM14.4 mice
 
Because several independent MM14.4 transgenic strains
were affected by psoriasiform dermatitis, it was apparent
that the transgene-expressing T cells were responsible.
We assumed, based on the CD4
 
 
 
 origin of the original
MM14.4 cell, that CD4
 
 
 
 cells should be responsible for the
dermatitis. However, to our surprise, several approaches
pointed at CD8
 
 
 
 cells as the perpetrators. First, lympho-
cytes infiltrating the skin expressed the CD8 coreceptor
(Fig. 3 A), were positive for TCR
 
 
 
, and were negative for
TCR
 
 
 
 and CD4 coreceptor (not depicted). Second, a ge-
netic approach has been used to investigate the role of
CD8
 
 
 
 cells. The analysis of several groups of mice derived
from two different founders (581 and 690) showed that the
disease developed in all mice independently of MHC class
II expression (Table I, A). In these experiments, two types
of KO mice were used: C2
 
 
 
 mice lacking A
 
 
 
b
 
 gene (8), and
mice with complete deletion of MHC class II region (B6;
129S-H2
 
dlAb1-Ea
 
/J) (C2
 
complete KO
 
; reference 16). This en-
sured that no cryptic MHC class II complexes (e.g., A
 
 
 
/E
 
 
 
hybrid molecules that are not detectable under normal cir-
cumstances, but may exist at levels recognizable by T cells)
were involved.
Figure 2. The features of psoriasiform dermatitis in MM14.4 
transgenic mice. Nontransgenic littermates (a–c) had normal-appearing 
skin and hair. In contrast, transgenic mice had loss of hair and scaling skin 
(d–h). c and f are enlarged areas framed in b and e, respectively. Lesions 
were characterized by thickening of the epidermis and intense scaling, 
mononuclear infiltrates in the epidermis and dermis, occasional subcorneal 
pustules (g), and focal parakeratosis (f and h). Epidermal hyperplasia was 
marked by loss of keratin 1 and 10 (i and j) and acquisition of expression 
of keratin 6 (k), typical for hyperplasia. Bar, 100  m. 
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By contrast, dermatitis was not observed in MM14.4
transgenic mice lacking MHC class I expression as a result of
targeted mutation of the 
 
 
 
2-microglobulin gene (
 
 
 
2m KO),
or in mice lacking classic MHC class I molecules (K
 
b
 
,D
 
b
 
 KO
mice;
 
 
 
Table I, A). To confirm the importance of CD8
 
 
 
 T
cells in disease development, we treated newborn MM14.4
transgenic mice with anti-CD8 monoclonal antibodies.
Treated mice did not develop dermatitis, or its severity was
attenuated compared with control mice (Fig. 3 B).
Finally, we tested directly the reactivity of CD8
 
 
 
 cells
from MM14.4 transgenic mice against DCs isolated from skin
of mice expressing A
 
b
 
Ep or lacking MHC class II (C2
 
 
 
 mice).
As shown in Fig. 3 C, purified CD8
 
 
 
 T cells from lymph
nodes of Rag1-deficient MM14.4 mice proliferated in re-
sponse to DCs isolated from skin of A
 
b
 
Ep and MHC class II-
negative mice; this indicated that CD8
 
 
 
 cells recognize syn-
geneic MHC class I molecules loaded with a skin-specific
peptide. Notably, CD8
 
 
 
 cells did not respond to splenocytes
from the same donors. The CD8
 
 
 
 MM14.4
 
 
 
 cells were
functional because they responded to splenocytes from
B10.BR mice of the H-2
 
k
 
 haplotype, to which MM14.4 has
a strong alloreactivity (against K
 
k
 
 molecule, see Fig. 5). The
overall conclusion from genetic and activation experiments
was that CD8
 
  cells were the primary effectors causing der-
matitis in MM14.4 mice. Given that original MM14.4 hy-
bridoma was CD4-positive and reacted to Ab MHC class II
molecules, we had to assume that MM14.4 TCR was capable
of interacting with MHC class II and class I molecules.
MM14.4 is a dual–MHC-restricted TCR
Dual MHC class I and class II reactivity of MM14.4 could
help to explain how a TCR that originates from CD4  T
cells may be responsible for an autoimmune disease that is
caused by CD8  T cells expressing the same TCR. However,
one possible caveat to this line of reasoning was the fact that
endogenous (nontransgenic) TCR chains are capable of mod-
ifying selection of T cells and the specificity of T cell re-
Figure 3. MM14.4 CD8  T cells are responsible for the psoriasiform 
dermatitis. (A) CD8  cells were found to infiltrate the epidermis (cryostat 
section, stained with anti-CD8 antibodies coupled to FITC; a 20  Fluotar 
objective). (B) Treatment of MM14.4 transgenic mice (strain 690) with anti-
CD8 monoclonal antibodies decreased the relative dermatitis score (  SE). 
(C) Skin DCs isolated from AbEp or MHC class II–negative C2  mice, but not 
their splenocytes, triggered proliferation of purified CD8  cells from 690 
transgenic Rag-1–deficient mice. B10.BR (H-2k) cells were used as positive 
control because MM14.4 CD8  cells have a strong alloreactivity to H2-Kk 
molecules. Combined data from two experiments.
Table I. Development of psoriasiform dermatitis in MM14.4 
TCR transgenic mice
Dermatitis incidence
Strain 0.581 Strain 0.690
Genotype of
MM14.4  mice Females Males Females Males
(%) (%) (%) (%)
A C1 C2 AbEp li  22/31 (71) 9/18 (50) 36/44 (82) 19/34 (56)
C1 C2  (A  ) 17/22 (77) 12/24 (50) 10/12 (83) 7/11 (63)
C1 C2complete KO 9/9 (100) 8/10 (80)
C1 C2 AbEp li  4/11 (36)
C1 C2  0/15 (0)
C1a C2 li a 0/22 (0) 0/18 (0)
C1 C2 li a 3/3
B C1 C2  TCR   3/3
C1 C2  TCR     3/3 1/2
C1 C2  TCR   13/13 (100)
C1 C2  TCR  TCR   24/26 (90) 14/20 (70)
C1 C2   MT 8/9 (88) 7/10 (70)
Disease was determined macroscopically as described in Materials and methods. Two 
MM14.4 strains, 581 and 690, were very similar in the disease development. Females 
generally were more susceptible than males. (A) Dermatitis development requires 
MHC class I expression. The frequency of dermatitis was independent of AbEp 
expression, but was affected by coexpression of AbEp and Ii due to the negative 
selection in the thymus (see also Fig. 4 B). MHC class I seemed to be indispensable for 
disease development. (B) T cells expressing endogenous (nontransgenic) TCR chains 
and B cells are not required for dermatitis development.
aThese mice still have MHC class II, and thus, were bred to Ii KO mice to reduce neg-
ative selection of MM14.4 cells, and C1 C2 li  mice were used as controls. The der-
matitis in these control mice was less severe than in C2 -KO mice, but was clearly 
detectable.
C1 ,  2-microglobulin KO; C2 , KO of A 
b; C1a , KO of classic MHC class I molecules 
Kb and Db; C2complete KO, deletion of all class II genes within MHC. JEM VOL. 202, July 4, 2005 77
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sponses (17, 18). Thus, an important question was whether
expression of endogenous TCRs could explain MHC class I
reactivity and cause the disease or contribute significantly to
its progression. To address this issue we performed extensive
breeding of MM14.4 mice to KO strains lacking genes en-
coding TCR chains, and observed KO mice for development
of dermatitis. Mice lacking endogenous TCR  chains,
TCR  chains, or both developed dermatitis (Table I, B).
Neither    T cells nor B cells was needed for development of
the disease, because MM14  mice carrying KO of TCR 
chain or of   heavy chain developed skin lesions. Thus, we
concluded that MM14.4 TCR-expressing cells are solely re-
sponsible for the disease. The disease was tolerant to mixing
the genetic backgrounds of mice during breeding to multiple
KO mouse strains (predominantly of the B6 genetic back-
ground). This alleviates the concern that autoimmunity in
AbEp mice resulted from the combination of genetic back-
grounds that contributed to the generation of these mice.
Overall, we concluded that CD8  T cells are critical for
the autoimmune dermatitis in MM14.4 mice, and, more-
over, that this receptor must have a dual MHC class I and
class II restriction. To confirm that, we analyzed MM14.4 T
cell selection in vivo and their reactivity in vitro.
Analysis of the selection of MM14.4 T cells in vivo re-
vealed that these cells could be found in CD4  and CD8 
compartments, and that MHC class I and class II contribute
to selection. The mode of MM14.4 TCR selection was an-
alyzed first using transgenic strains 581 and 690 crossed to
mice lacking the Rag1 recombinase gene. The results ob-
tained with strain 690 are representative of a common pat-
tern of MM14.4 selection (Fig. 4 A). CD4  and CD8  cells
were positively selected in MM14.4 TCR transgenic Rag-
negative mice that expressed no endogenous class II mole-
cules, but expressed AbEp and MHC class I. Although the
selection of CD4  cells was weak, in the absence of MHC
class II the CD4  population was almost completely absent,
Figure 4. The pattern of MM14.4 T cell selection and lineage com-
mitment reflects their dual MHC class I and MHC class II recognition. 
(A) CD4  and CD8  cells were positively selected in MM14.4.690 transgenics 
bred to Rag1-deficient background. The MHC and Ii genotypes are shown, 
as well as total cellularity [  10 6] of the thymus and peripheral lymph 
nodes. Selection into CD4  lineage was dependent on AbEp expression, 
while selection into CD8  lineage was not. Expression of variable Ab/pep-
tide repertoire in C2 Ii  mice (Ab-positive, Ii-positive), AbEp Ii  mice, and 
C2 Ii  (Ab-positive, Ii-negative) mice led to negative selection of MM14.4  
T cells. (B) Reactivity of the lymph node cells from Rag1  MM14.4.690 
transgenic mice with stimulators of variable MHC background confirms the 
pattern of positive and negative selection of the MM14.4 TCR. Mice used as 
donors of responding cells (FACS analysis is shown in A) were AbEp mice 
(Ab-negative, AbEp-positive, Ii-negative), C2  mice (mice with no MHC class II), 
or C2 Ii  mice (Ab-positive, Ii-positive). Proliferation of 3   105 responders 
mixed with 5   105 of B6 (Ab-positive, left) or B10.BR (H-2Kk- positive, 
right) irradiated splenocytes. (C) Selection of CD8  MM14.4  T cells re-
quired expression of MHC class I molecules. MM14.4 mice lacking MHC 
class I because of genetic deletion of the  2-microglobulin had very few 
CD8 single-positive cells in the thymus and in the periphery independently 
of AbEp expression (top and middle), as compared with MHC class I–sufficient, 
MHC class II–negative mice (bottom). Numbers in brackets show absolute 
numbers of CD8 ,V 2  cells ( 10 6) in the thymi and lymph nodes. Core-
ceptor FACS dot-plots are shown for cells gated on V 2-positive cells.BIASED MHC–PEPTIDE REPERTOIRE AND AUTOIMMUNITY | Logunova et al. 78
and confirmed that AbEp was used as a positively selecting
ligand for this T cell subset. Positive selection into the
CD8  lineage was dramatically more efficient, and was in-
dependent of the presence of AbEp. At the same time, the
thymi of mice in these two groups (C2 Ii AbEp  and
C2 Ii , Fig. 4 A, top two panels) were moderately sized and
contained elevated numbers of double-negative cells. This
suggested that some cells may be stimulated strongly enough
to lose their coreceptors or to be eliminated by negative se-
lection. Nevertheless, substantial numbers of MM14.4  T
cells were found in the periphery (Fig. 4 A, right) and were
functional (Fig. 4 B). As expected, expression of the WT
class II (Ab) molecules with Ii led to a very strong negative
selection at the double-positive stage of thymocyte devel-
opment; CD4 and CD8 lineages were reduced in relative
and absolute numbers. Less severe depletion was detected in
mice that did not have endogenous Ab molecules but were
AbEp and Ii positive. The reactivity of MM14.4 cells se-
lected by different MHC backgrounds correlated well with
the antibody staining data (Fig. 4 B); reactivity of T cells to
Ab (mediated by CD4  cells, Fig. 5) was dependent on the
presence of AbEp during selection and was obliterated by
negatively selecting Ab molecules. At the same time, reac-
tivity to allo MHC class I molecule Kk (used as a simple
measure of CD8  reactivity, Fig. 5) was independent of the
presence of AbEp during selection, but was diminished se-
verely by the WT Ab present during selection; these con-
firmed that negative selection had happened at the double-
positive stage of thymic development.
To show that the selection of CD8 MM14.4  T cells
was MHC class I dependent, we analyzed selection in
MM14.4 transgenic mice lacking  2-microglobulin (C1 
mice). It was clear that CD8  single-positive cells in the thy-
mus and CD8  cells in the periphery were reduced very sig-
nificantly in mice lacking MHC class I, and that the presence
of AbEp did not allow positive selection of these cells (Fig. 4
B, note that the numbers in brackets show absolute number  
10 6 of CD8 V 2  single-positive cells and not the total
cellularity of the organs). Mice used in this experiment were
Rag-sufficient, but even so, the lack of positive selection of
MM14.4 into the CD8 lineage was obvious. We also tested
MM14.4 mice lacking only classic MHC class I molecules,
Kb and Db. T cell selection in these mice is complicated by
the inevitable presence of the WT MHC class II molecule,
Ab. To diminish the negative effect of Ab, we crossed these
mice to Ii-negative mice. Although lymph nodes from
MHC class I–sufficient C2 Ii  MM14.4  mice had  4  
106 CD8 V 2  cells, these cells were practically absent from
mice lacking classic MHC class I molecules.
The T cell selection patterns in MM14.4 transgenic mice
correlated well with the incidence of dermatitis (Table I, A);
the presence of the WT Ab molecules reduced the incidence
Figure 5. Dual MHC-reactivity and coreceptor-dependence of 
MM14.4 TCR. (A) CD4 , MM14.4 T cells recognize Ab MHC class II mole-
cules, while CD8 , MM14.4 T cells recognize Kk MHC class I molecules. 
T cell lymphoma cells transfected with MM14.4 TCR chains alone (double-
negative, DN) or cotransfected with CD4 or CD8 c-DNA were tested for 
IL-2 production in response to MHC class II and class I molecules (left). 
Reactivity of CD4  cells was inhibited by anti-Ab and anti-CD4 mAb (middle), 
while reactivity of the CD8  cells was inhibited by anti-Kk and anti-CD8 
mAb (right). Color conversion of Alamar Blue by IL-2–dependent cell line 
was used to measure IL-2 in culture medium. CD8 was a CD8 ,  dimer 
transcribed from a polycistronic matrix. (B) Recognition of MHC class II by 
MM14.4 required CD4 interaction with MHC class II molecules. CD4  
MM14.4-transfected T cells reacted to Ab-positive stimulators (B6 or WT 
Ab-transgenic, Ab WT) but not to stimulators that expressed Ab with inacti-
vated CD4 binding site (Ab MUT; left). The presence or absence of CD4 did 
not matter for activation with plate-bound anti-CD3 antibodies (right).JEM VOL. 202, July 4, 2005 79
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of the disease, and the absence of MHC class I molecules al-
leviated the disease completely.
Transfection of cloned MM14.4 TCR chains into a T
cell lymphoma allowed us to address directly the dual-MHC
restriction of MM14.4 and the role of coreceptors in antigen
recognition (Fig. 5). We found that recognition of MHC
class II by MM14.4 was completely dependent on the CD4
expression by MM14.4 T cells (Fig. 5 A, left) and on the
CD4–MHC class II interaction (Fig. 5 B). CD4  MM14.4
cells recognized Ab molecules on B6 splenocytes indepen-
dently of MHC class I because B6. 2m-negative splenocytes
were as stimulatory to them as were WT splenocytes (Fig. 5
A, left). At the same time, the MM14.4 recognition of
MHC class I molecules was CD8-dependent (Fig. 5 A, left);
CD8  MM14.4  T cells did not react to MHC class II Ab
molecules, but were activated by MHC class II–negative
Ltk  cells of H-2k MHC haplotype. These reactivity patterns
were confirmed by blocking with mAb against MHC mole-
cules and against the coreceptors (Fig. 5 A, middle and right
panels for CD4  and CD8  cells, respectively). In addition,
MM14.4 cells expressing CD4 were unable to react to sple-
nocytes from mice expressing mutant Ab molecules lacking
the CD4 binding site (Ab MUT; reference 19; Fig. 5 B).
Experiments described in this section demonstrated that
(a) MM14.4 clearly has dual restriction, and interacts with
MHC class I and class II; (b) AbEp is a positively selecting
ligand for CD4 MM14.4  cells, but not for CD8 
MM14.4  T cells; and (c) dual MHC restriction of MM14.4
is heavily dependent upon the coreceptors.
Biased MHC class II/peptide repertoire favors selection of 
TCRs with highly degenerate specificity
Thus, we have established a possible link between expres-
sion of extremely limited MHC class II/peptide repertoire
and generation of autoimmune CD8  T cells. We reasoned
that biased MHC–peptide repertoire is likely to allow posi-
tive selection of a larger proportion of TCRs that is less de-
pendent on recognition of a specific selecting peptide.
Therefore, it is likely that the degeneracy of T cell selection
by a biased peptide repertoire will result in increased num-
bers of TCRs with multiple cross-reactivities, including
those with recognition of both MHC classes. To test this
hypothesis, we performed a comparative analysis of the oc-
currence of dr-TCRs in B6 and AbEp mice using dual
MHC restriction as a measure of TCR promiscuity (Table
II). To ensure that only one TCR  chain per T cell was
expressed, we crossed AbEp mice to B6.TCR -negative
mice, and then intercrossed them to produce AbEp mice
with a single copy of the TCR  locus. Before the fusion, T
cells were activated in vitro with irradiated splenocytes ex-
pressing disparate MHC class II molecules. Because the
coreceptors may be important for activation of low-affinity
TCRs, to provide dual-reactive TCRs with the coreceptor
needed for MHC class I recognition, we made the fusion of
activated T cells and BWZ CD8  lymphoma cell line (20).
The first round of hybridoma screening revealed MHC
class II–reactive individual hybridoma cultures (total of
5,664 cultures tested, 4,437 were MHC class II reactive),
which were tested individually for activation by a panel of
11 fibroblastoid cell lines (21) which originated from differ-
ent mouse strains and expressed MHC class I but not class
II molecules. Positive cultures (54 cultures) were subcloned
several times and karyotyped to exclude a possibility of a
triple-cell fusion. 14 of 15 TCRs from dual-restricted cells
were cloned, sequenced, expressed in a T cell lymphoma
cell line, and their unique specificities were confirmed by
an in vitro activation of the transfectants. The results of
these experiments are shown in Table II. Clearly, AbEp
mice selected more (at least by an order of magnitude) dr-
TCRs than did their control counterparts. We found no
apparent bias in TCR V  and V  region usage in dual-
restricted T cells (Table III).
Table II. Mice with restricted MHC class II–peptide repertoire produce increased numbers of TCRs with dual MHC 
(class II/class I) restriction
Dual restricted hybridoma clones
Group
Normal fusion
partner
Activated
with
Total no. of
hybridomas
tested
Hybridomas
reactive to
MHC class II
Before
cloning
After
cloning
Frequency of 
dual-restricted
clonesa
I B6 TCR  /  A bm12 2,278 2,185 12 2
II B6 TCR  /  H-2q 480 364 5 0
Total 2,758 2,549 2   1:1,275
III AbEp TCR  /  B6 1,920 1,886 36 12
IV AbEp ConA 986 2 1 1
Total 2,906 1,888 13  1:145
Estimation of relative frequencies of dual MHC class I/ MHC class II–restricted T cells in control (B6) mice and in AbEp mice by direct testing of MHC class II–reactive hybridomas 
against a panel of MHC class I–positive, class II–negative fibroblastoid cell lines. Mice used in groups I–III had one copy of the TCR  locus, and BW5147 TCR-negative, CD8-
positive cell line was used as a fusion partner in these groups. Mice in group IV had two copies of TCR  locus, but no evidence of an additional productive rearrangement of the 
TCR  locus was found in MM14.4 hybridoma belonging to this group (not depicted). BW5147 TCR-negative, coreceptor-negative cell line was used as fusion partner in this group.
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Thus, limited MHC class II/peptide repertoire supports
selection of T cells carrying TCRs with highly degenerate
MHC recognition.
DISCUSSION
Autoimmunity linkage with MHC alleles is well-established.
However, the exact mechanisms of such linkage are not
clear. It also is unclear how the well-documented involve-
ment of MHC class I–reactive CD8  T cells in the patho-
genesis of autoimmune diseases fits with autoimmunity link-
age to MHC class II genes. Our study suggests answers to
these problems.
Limitation of MHC–peptide repertoire leads
to autoimmunity
MHC alleles associated with autoimmunity are believed to
be unable to provide adequate negative selection because of
a low affinity of MHC interactions with potentially hazard-
ous peptides (22, 23) or a low avidity of TCR interactions
with MHC–peptide complexes (24, 25). Because autoim-
munity-associated MHC class II molecules have structural
features which limit the pool of peptides that they can bind
(3–5), we hypothesized that the key to such association is
in the biased peptide repertoire presented by autoimmu-
nity-prone MHC molecules. This biased (or limited) pep-
tide repertoire leads to incomplete negative selection,
which normally contributes to the shaping of the TCR
repertoire by removing highly specific autoreactive recep-
tors (26) and promiscuous receptors (27). It also may sup-
port positive selection of T cells carrying promiscuous
receptors. TCRs with promiscuous receptors must be pro-
duced constantly in normal mice by a random association
of germline-encoded segments of the TCR and other
diversification mechanisms accompanying recombination.
However, because the size of the T cell compartment is
limited, the TCRs that are best fit for interactions with
MHC–peptide complexes have a selective advantage and
fill it to capacity. The limitation of peptide diversity places
T cells with regular TCRs at a disadvantage and increases
the relative input in the TCR pool of the otherwise out-
numbered nonconventional TCRs.
In several studies, autoimmunity was obliterated by
transgenic expression of “good” MHC molecules along with
“bad” (autoimmunity-prone) host MHC (28–30). One ex-
planation for these results is that transgenic MHC molecules
caused negative selection of TCRs with promiscuous recog-
nition of multiple MHC molecules (28). It also is possible
that expression of an additional and different MHC protein
stimulates robust positive selection, and resulting T cells out-
number the potentially autoreactive T cells selected by a dis-
ease-prone MHC. This is a likely scenario in the case of the
HLAQ062 molecule being protective for type 1 diabetes
(31, 32). Its recently determined crystal structure suggests an
expanded peptide repertoire presented by this molecule
compared with the repertoire presented by homologous DQ
molecules associated with type 1 diabetes (32).
Our experimental approach involved studies of mice
with an extremely limited MHC class II/peptide repertoire
(8). These mice developed multiple autoimmune reactions
(Fig. 1), and when a TCR from such mice was overex-
pressed as a transgene (MM14.4), they developed an organ-
specific autoimmunity (Fig. 2). A CD4  T cell–mediated
autoimmune reaction in independently generated AbEp mice
also has been reported (33).
Table III. TCR  and   chain usage by dual-restricted hybridomas
Origin Hybridoma clone V  J  V  J  MHC I
B6, TCR  /  
group I
4F5 TRAV10(D) TRAJ17  TRBV14 TRBJ2-1 Kbm1, H-2u,s
IG2A TRAV6D-4 TRAJ31  TRBV2 TRBJ1-1 H-2q
AbEp, TCR  /  
group III
17a3 TRAV5D-4 TRAJ45  TRBV12-2 TRBJ2-2 Dd
19d4 TRAV7-3 TRAJ43 TRBV19 TRBJ2-3 H-2q
21d1 TRAV14D-3 TRAJ33 TRBV13-2 TRBJ2-7 Dq
24d5 TRAV14D-1 TRAJ49 TRBV1 TRBJ2-4 H-2k
27b3 TRAV8D-1 TRAJ47 TRBV3 TRBJ2-7 Kbm3
37b1 TRAV3-1 TRAJ50 TRBV13-1 TRBJ2-1 Kbm1, H-2s
40a1 TRADV16D TRAJ32 TRBV14 TRBJ2-1 Kbm1, H-2s
42a2 TRAV13-1 TRAJ48 TRBV12-2 TRBJ2-4 Kbm3
44a4 TRAV3(D)-3 TRAJ6  TRBV12-1 TRBJ2-7 H-2k
49c6 TRAV5D-4 TRAJ22 TRBV19 TRBJ1-1 H-2k
8-1-6 TRAV4D-3 TRAJ30 TRBV15  TRBJ2-7 H-2u
AbEp, ConA 
group IV
MM14.4 TRAV14D-2 TRAJ26 TRBV3 TRBJ2-1 Kk
All cells reacted to Ab. Their MHC class I cross-reactivity is shown in the right column. Where the exact molecule has not been identified, the whole MHC haplotype is shown. 
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Autoimmunity was found only in older AbEp mice and
was rather mild and suggested that the activity of self-reac-
tive T cells could be controlled by suppressor T cells. Closer
examination showed that AbEp mice have a robust popula-
tion of suppressor T cells (Fig. S1, A and B, Table S1, and
supplemental Materials and methods, available at http://
www.jem.org/cgi/content/full/jem.20050198/DC1) which
suppressed dermatitis development in MM14.4 transgenic
mice upon adoptive transfer (Fig. S1 C). These data imply
that autoimmunity observed in AbEp mice is quenched by
active suppression.
AbEp mice are an extreme case of the biased MHC class
II/peptide repertoire. Autoimmunity-prone MHC alleles in
humans and rodents have a much broader peptide repertoire.
In our own experiments and experiments of Ignatowicz’s
group (13), AbEp mice expressing Ii—and having  70% of
the covalently bound E  peptide replaced by other pep-
tides—developed autoimmune responses (Fig. 1). Thus,
even partial, incomplete restriction of the MHC–peptide
repertoire may promote autoimmunity; this suggests that this
may be a significant part of the mechanism by which au-
toimmunity-prone MHC molecules function.
Dual MHC class I and II restriction of TCRs selected by biased 
peptide repertoire may explain MHC class II linkage of MHC 
class I–driven autoimmunity
To our surprise, MM14.4 TCR originally cloned from a
CD4  hybridoma was found in transgenic mice, predomi-
nantly expressed by the CD8 lineage T cells, which also were
responsible for the dermatitis. Further examination showed
that MM14.4 is a truly dual-MHC class I/MHC class II–
restricted TCR (Figs. 4 and 5). Spontaneous infiltrates around
the pancreatic islets in non-TCR transgenic AbEp mice (Fig.
1 B) consisted predominantly of CD8  T cells; these indi-
cated that other autoimmune TCRs behave similarly to
M14.4 and that AbEp mice select more of such receptors.
Receptors with dual-MHC restriction can be selected by
normal MHC–peptide repertoire (reference 34, Table II),
but that is more of an exception. Direct comparison of the
relative frequencies of the dr-TCRs in B6 and AbEp mice
showed that the latter select  10 times more dr-TCRs than
do normal mice (Table II). It is likely that dr-receptors have
a bias toward recognition of broad framework MHC deter-
minants, which allows them to interact with both MHC
classes. The TCR structural features that allow these interac-
tions have not been determined. The V region usage in  
and   chains seems to be broad (Table III). Similarly, se-
quences of the CDR3  regions do not contain an obvious
motif (Table S2, available at http://www.jem.org/cgi/
content/full/jem.20050198/DC1). The only unusual feature
is the presence of a bulky tryptophan residue in the CDR3
regions of the   chains of many of these receptors (Table S3,
available at http://www.jem.org/cgi/content/full/jem.
20050198/DC1). The significance of this observation re-
mains to be determined.
Under normal circumstances, dr-receptors are likely to
be removed by unrestricted MHC–peptide repertoire due to
a high overall avidity of interactions with both MHC classes
and coreceptors. The CD8  compartment in mice lacking
CD4 molecules contained increased numbers of MHC class
II–reactive cells compared with normal CD4-sufficient mice
(35). Conversely, a biased peptide repertoire allows dual-
restricted TCRs to slip through negative selection by MHC
class II, and promotes their positive selection into the CD4
lineage. In addition, under conditions of a biased peptide rep-
ertoire, other factors, such as MHC-peptide complex density
and the presence of functional coreceptors, may compensate
for the lack of TCR–peptide interactions. Dependence of the
T cell activation on the coreceptors was associated with a low
affinity of TCR–MHC interaction (36). Coreceptors may
contribute to positive selection by enforcing signaling through
the TCR (37) or by increasing the overall avidity of the
TCR-coreceptor-MHC–peptide complex (38, 39).
It is well-established that CD8  T cells participate in the
development of organ-specific autoimmune diseases, such as
type 1 diabetes. However, diabetes-prone animals do not
have unique MHC class I molecules, whereas MHC class II
is linked clearly to diabetes development. It is possible that
selection of promiscuous diabetogenic receptors (40) follows
the same rules that we have observed in mice with biased
MHC class II/peptide repertoire; however, this issue awaits
further examination. Dual-restricted receptors are likely to
be an extreme example of TCR promiscuity, and it would
be naive to claim that they are the exclusive source of au-
toreactive TCRs. Nevertheless, because biased peptide rep-
ertoire selects more of these receptors and leads to various
forms of autoimmune reactions (including dermatitis caused
by MM14.4), they may make an important contribution to
the autoimmune pool of TCRs. It is intriguing that a sub-
stantial subset of the naturally occurring dual MHC-
restricted TCRs described so far (Table S4, available at http:
//www.jem.org/cgi/content/full/jem.20050198/DC1; the
list contains TCRs with proven or potential dual MHC class
restriction) is involved in autoimmune reactions.
Thus, a biased MHC class II–peptide repertoire facilitates
selection of aberrant, highly promiscuous TCRs. This is an
important prerequisite for the development of autoimmu-
nity; however, the clinical outcome undoubtedly is influ-
enced by additional factors, such as suppressor T cell activity,
that reflect the complicated genetics of autoimmunity.
MATERIALS AND METHODS
Mice and genotyping. Mice expressing no endogenous MHC class II
and Ii (C2 ) and C2  mice expressing AbEp complexes (AbEp mice) were a
gift from P. Marrack (National Jewish Medical and Research Center, Den-
ver, CO). BALB/cJ, C57BL/6J (B6), B10.BR-H2k2 H2-T18a/SgSnJ
(B10.BR), C3H/HeJ, B6.C-H2bm12/KhEg (bm12), B6.129P2- 2mtm1Unc
( 2m KO), C57BL/6J-Rag1tm1Mom (Rag1 KO), B6.129S-Tcratm1Mom
(TCR   KO), B6.129S-Tcrbtm1Mom/J (TCR   KO), B6.129S-
Tcrbtm1MomTcrdtm1Mom/J (TCR ,  KO), B6.129-H2dlAb1-Ea/J (C2complete KO),
B6.129.S2-Igh-6tm1Cqn/J (B cell  mice), B6.129S6-Iitm1Liz/J (Ii KO), andBIASED MHC–PEPTIDE REPERTOIRE AND AUTOIMMUNITY | Logunova et al. 82
B6.129-H2-DMatm1Luc (DM KO) mice were obtained from The Jackson
Laboratory. Mice lacking classic MHC class I molecules, Kb and Db (41),
were provided by D. Roopenian (The Jackson Laboratory). TCR  KO
mice were genotyped by Southern blotting as described (42). Mice lacking
Rag1 and  2m were typed by staining with anti-Ig (to detect the loss of B
cells) and anti–MHC class I antibodies, respectively. Mice expressing trans-
genic MHC class II Ab molecules (AbWT) and Ab with disrupted CD4-bind-
ing site (AbMUT; reference 19) were maintained at the Jackson Laboratory
animal research facility. Animal research protocols were approved by The
Jackson Laboratory Animal Care and Use Committee.
TCR cloning and transgenic mice. Lymph node T cells from AbEp
mice were stimulated with ConA and fused with the TCR-negative
BW5147 thymoma. Hybridomas were tested for IL-2 production after
stimulation with B6 splenocytes. A CD4  subclone MM14.4 was chosen
for future experiments. MM14.4 expressed V 2 as determined by staining
with a panel of mAb obtained from BD Biosciences. The V  region
(V 16.2) was determined by PCR with a set of  -specific primers (43).
cDNA for   and   chains were prepared by RT PCR, cloned into a TA
vector (Invitrogen), and sequenced. Primers were designed to amplify the
V 2.5-J 20 and V 16.2-D 2.1-J 2.1 regions from MM14.4 genomic
DNA. The resulting fragments were subcloned into pT  and pT  genomic
TCR-cassette vectors (a gift from D. Mathis, Harvard Medical School, Bos-
ton, MA) as described previously (44). The new constructs were tested for
expression by transfection (along with CD4 cDNA) into the 4G4 cell line,
which expresses CD3 but no endogenous   or   TCR chains. The reactiv-
ity of the transfectants was not different from that of the initial MM14.4 hy-
bridoma and was blocked by anti-Ab mAb. These results confirmed that this
was the correct and functional construct. DNA fragments encoding   and  
chains were coinjected into (B6xBALB/cBy)F1 oocytes fertilized by
C2 ,AbEp  transgenic males. Of seven independent founders, integration of
both TCR chains was detected in five of them.
Dual-restricted TCRs from hybridomas. Lymph node cells from mice
carrying one copy of TCR -locus with normal MHC class II (Ab) or AbEp
were activated in vitro with allo MHC class II (bm12 or Aq) and WT Ab
MHC class II, respectively, and were fused to CD8  BWZ lymphoma cell
line (a gift from N. Shastri, University of California, Berkeley, CA; reference
20). All hybridomas were tested first in IL-2 production assay (described in
the T cell activation section) for reactivity with the immunizing MHC class II
molecules in the presence or absence of blocking anti–MHC class II antibod-
ies. Positive MHC class II–reactive cultures were tested for activation by a
panel of 11 SV40-transformed MHC class II–negative, MHC class I–positive
fibroblasts from different mouse strains (21). Positive cultures were subcloned
multiple times, and karyotyped to ensure that they did not result from fusion
of three cells. TCR chains were cloned exactly as described for MM14.4.
Dermatitis severity was determined as follows: 1, small lesions ( 1 cm2)
on the ventral trunk; 2, larger lesions, but still localized only to the ventral
trunk; 3, scattered lesions on the ventral and dorsal sides; 4, lesions on the
entire trunk and head; 5, similar to 4 but with visible exudate.
Monoclonal antibodies and FACS analysis. All fluorochrome-labeled
mAbs were purchased from BD Biosciences except for anti–CD8-Quantum
red and anti–mouse Ig Fc fragment polyclonal antibodies labeled with FITC
(Sigma-Aldrich) and anti–CD4-Red613 (GIBCO BRL). Purified anti–
MHC class II antibodies and anti-CD3  mAb 145-2C11 were obtained
from the Yale University Hybridoma Facility. Data collection on the FACS-
Calibur flow cytometer (Beckton Dickinson) and subsequent analysis was
performed using CELLQuest software.
In vivo elimination of CD8  T cells was done by i.p. injection of 50
 g/mouse of anti-CD8 mAb YTS169.4 (45) every other day for 2 wk start-
ing at 7–10 d post partum.
Histology and immunohistochemistry. Tissues were fixed and stained
with hematoxylin-eosin by standard methods. Cryosections of pancreas, thy-
roids, salivary glands, and skin were stained with FITC-conjugated anti-CD4
(Caltag), anti-CD8, and anti-CD3 (BD Biosciences). Antikeratin staining
was done on paraffin sections. Endogenous peroxidase was quenched with
3% H2O2, and sections were stained overnight with antisera to keratins 1, 6,
and 10 (Babco); washed in PBS; and incubated with biotinylated secondary
antibody and streptavidin–horseradish peroxidase. Positive reaction was de-
tected with diaminobenzidine (Vector Laboratories), and sections were
counterstained with hematoxylin. ANA staining was performed by indirect
immunofluorescence using HEP-2–coated slides (RHI Gene Inc.).
T cell and skin DC purification. CD4  and CD8  T cells were isolated
from lymph node cells by treatment with mAbs against MHC class II (Y3JP;
reference 46) and anti-CD8 (53–6.72; reference 47) or anti-CD4 (GK1.5;
reference 48), respectively, for 45 min at 4 C (107 cells per ml of culture su-
pernatant) followed by negative selection with the mixture of magnetic
beads (anti–mouse IgG, anti–mouse IgM, anti–rat IgG) from PerSeptive
Biosystems according to the manufacturer’s protocol. For T cell depletion, a
mixture of anti-CD8 and anti-CD4 (GK1.5) mAbs was used, followed by
treatment with anti–rat Ig magnetic beads. DCs were purified from ventral
and dorsal skin of AbEp and C2  mice as described previously (49).
T cell activation. T cell proliferation was measured by 3H-thymidine in-
corporation after 3 d of cocultivation of 2   105 spleen or lymph node cells
with 2   105 irradiated (2,000 rad) stimulator splenocytes in 96-well plates
(Becton Dickinson) in 150  l of culture medium [Click’s EHAA Medium
(Irvine Scientific) supplemented with 5% FCS (Sigma-Aldrich), 20 mM
L-glutamine (GIBCO BRL), 5   10 5 M  -mercaptoethanol (Bio-Rad
Laboratories) and 100 U/ml penicillin/streptomycin mixture (GIBCO BRL)].
2   105 of purified CD8  T cells from Rag-negative MM14.4 mice were
activated with 5   104 skin DCs. The range of proliferation was 1–1.8   102
cpm in DCs or T cells alone, or T cell   splenocyte controls, and 2–4   103
in cocultures of responder T cells and skin DCs. 2.5   104 T cell hybridomas
or TCR transfectants were activated by cultivation with 105 stimulator cells
or by plate-bound anti-CD3 mAb; IL2 production into the medium was
measured by proliferative response of the IL-2–dependent cell line CTLL us-
ing Alamar Blue (Biosource International) color conversion assay.
Western blotting was performed on lysates of CD4-enriched lymph node
cells. Lysates were prepared using 1% NP-40 (Sigma-Aldrich) in 0.1 M Tris
buffer (pH 7.4) supplemented with “complete mini” protease inhibitor cock-
tail (Roche Diagnostics Corp.). Lysates were loaded at different volumes to
match the cell equivalents of CD4  cells as determined by FACS staining after
negative selection of B cells and CD8  cells with magnetic beads. Donkey
anti–rabbit horseradish peroxidase–conjugated antibodies (Jackson Immu-
noResearch Laboratories) were used as secondary antibodies. Blots were devel-
oped with the enhanced chemiluminescence reagent (Amersham Biosciences).
Online supplemental material.  Supplemental Materials and methods
and Fig. S1 show evidence that AbEp mice have elevated levels of T sup-
pressor cells that express FoxP3 and are capable of blocking dermatitis in
MM14.4 TCR transgenic mice upon transfer into newborn mice. Table S1
shows age-dependent accumulation of activated T cells in AbEp mice. Ta-
bles S2 and S3 show V and CDR3 regions of   and   chains, respectively,
of cloned TCRs with dual-MHC restriction. Table S4 lists examples of
TCRs with known or strongly implied dual MHC restriction and their rel-
evance to autoimmunity. Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20050198/DC1.
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